/

Società

Al

Non verificato

Alys Pharmaceuticals

Di cosa scriviamo

BiologiaFarmaceuticaSanità

3 comunicati stampa

Guarda tutti i comunicati

10/06/2025

Farmaceutica

Sanità

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

Fonte

Alys Pharmaceuticals

Emittente

1.00

0

27/03/2025

Farmaceutica

Sanità

Biologia

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

Fonte

Alys Pharmaceuticals

Emittente

1.00

0

04/02/2025

Farmaceutica

Sanità

Biologia

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

Fonte

Alys Pharmaceuticals

Emittente

1.00

0

Seguaci

0

Compatibilità

0